Metrics to compare | 6634 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6634PeersSector | |
|---|---|---|---|---|
P/E Ratio | −37.4x | −8.9x | −0.5x | |
PEG Ratio | −2.16 | 0.06 | 0.00 | |
Price/Book | 4.2x | 2.3x | 2.6x | |
Price / LTM Sales | 98,591.1x | 5.9x | 3.1x | |
Upside (Analyst Target) | - | 60.4% | 53.0% | |
Fair Value Upside | Unlock | −16.1% | 6.3% | Unlock |
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.